Posts in Biotechnology


Superbugs Require New Weapons: Strong, Effective Intellectual Property Rights May Be Our Best, Last Hope

The dangers of killer germs and superbugs are not limited to bird flu in China, Ebola in West Africa, Zika in South America and MERS in the …
By Dr. Kristina Lybecker
8 months ago 3

PwC patent litigation study shows recent drop in lawsuits despite increasing patent grants

About 5,100 patent infringement cases were filed in the U.S. during 2016, according to the PwC litigation study. This represents a 9 percent drop in lawsuits from 2015’s totals …
By Steve Brachmann
8 months ago 2

Lex Machina ANDA litigation report shows recent decline in case filings and top parties in filings

Lex Machina recently released a Hatch-Waxman/ANDA litigation report detailing trends and key findings from pharmaceutical cases filed in U.S. district courts between January 1st, 2009, and …
By Steve Brachmann
9 months ago 0

Focus on Stronger IP Incentives: Price Setting is Not the Cure for Healthcare Spending

The WHO is gathering governments, academics and activists in Amsterdam next month to discuss price setting options for medicines. But the so-called Fair Pricing Forum ignores the …
By Dr. Kristina Lybecker
9 months ago 0

Bristol-Myers Squibb, Pfizer file ANDA lawsuits against makers of generic Eliquis

American drugmakers Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) fired off a series of nine lawsuits to prevent generic versions of Eliquis, a …
By Steve Brachmann
10 months ago 0

Other Barks for Wednesday, April 5th, 2017

Google tries to strike a “patent peace” with a new cross-licensing initiative for Android developers. The Federal Circuit is petitioned for review of a judgment in a …
By Steve Brachmann
10 months ago 1

Regeneron, Sanofi-Aventis sue for declaration that dermatitis treatment Dupixent doesn’t infringe Amgen patent

Although Dupixent hasn’t been granted FDA approval as of yet, the drug has made it further than Amgen’s AMG-317, the code name for Amgen’s …
By Steve Brachmann
10 months ago 0

The Plight of the Public Sector Entrepreneur

Being an entrepreneur isn't easy. While it is a tough road for anyone, it's particularly tough if you're in the public sector and threatened by politicians... Rather, …
By Joseph Allen
10 months ago 1

University of California seeks assignment of nanopore patents from former grad student

At the center of the legal spat is the proper assignation of a series of patents covering DNA sequencing technologies, which UC alleges were developed while the …
By Steve Brachmann
10 months ago 1

Hysteria over creeping bentgrass leads to Oregon bill targeting GMO patent owners

In early February, a bill was introduced into the Oregon House of Representatives, which could make the state seem much less friendly to patent owners, specifically those …
By Steve Brachmann
10 months ago 5

USF files patent suit over sale of Alzheimer’s research mice

On Tuesday, March 21st, a pre-trial hearing will take place in a case involving patent infringement claims targeting the sale of mice having mutated genes which make …
By Steve Brachmann
10 months ago 0

CRISPR patent interference ended by USPTO because parties’ claims do not interfere

The PTAB concluded: "Based on our determination that the preponderance of the evidence shows there is no interference-in-fact between the parties’ claims, we need not decide the …
By Gene Quinn
11 months ago 3

Sportbrain files smartwatch fitness tracker patent suits against Apple, HP, Michael Kors and New Balance

At the center of each lawsuit is the assertion of a single patent covering personal data collection technology integrated into a series of smartwatches. The patent-in-suit asserted …
By Steve Brachmann
12 months ago 2

FTC revives complaint, files motion for stipulated order over pay-for-delay agreement for generic Lidoderm

On January 23rd, the Federal Trade Commission (FTC) announced that it had taken steps to resolve antitrust charges involving business activities employed by Irish/U.S. drugmaker …
By Steve Brachmann
12 months ago 2

Merck agrees to $625 million payment, royalties to Bristol-Myers Squibb for sales of Keytruda cancer treatment

On January 20th, NYC-based drugmaker Bristol-Myers Squibb Co. (NYSE:BMY) and Kenilworth, NJ-based pharmaceutical firm Merck & Co. (NYSE:MRK) announced that the two companies had entered into …
By Steve Brachmann
12 months ago 0